Target Price | $67.00 |
Price | $41.85 |
Potential |
60.10%
register free of charge
|
Number of Estimates | 9 |
9 Analysts have issued a price target Celldex Therapeutics, Inc. 2025 .
The average Celldex Therapeutics, Inc. target price is $67.00.
This is
60.10%
register free of charge
$90.00
115.05%
register free of charge
$37.00
11.59%
register free of charge
|
|
A rating was issued by 10 analysts: 9 Analysts recommend Celldex Therapeutics, Inc. to buy, 1 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Celldex Therapeutics, Inc. stock has an average upside potential 2025 of
60.10%
register free of charge
|
Dec '23 |
2024 Estimates |
|
---|---|---|
Revenue Million $ | 6.88 | 4.59 |
191.53% | 33.32% | |
EBITDA Margin | -2,020.78% | -4,185.29% |
54.88% | 107.11% | |
Net Margin | -2,813.05% | -3,568.65% |
58.27% | 26.86% |
8 Analysts have issued a sales forecast Celldex Therapeutics, Inc. 2024 . The average Celldex Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
1 Analyst has issued an EBITDA forecast Celldex Therapeutics, Inc. 2024 . The average Celldex Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
9 Celldex Therapeutics, Inc. Analysts have issued a net profit forecast 2024. The average Celldex Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '23 |
2024 Estimates |
|
---|---|---|
Earnings Per Share $ | -2.92 | -2.47 |
21.67% | 15.41% | |
P/E | negative | |
EV/Sales | 422.58 |
9 Analysts have issued a Celldex Therapeutics, Inc. forecast for earnings per share. The average Celldex Therapeutics, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Celldex Therapeutics, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Celldex Therapeutics, Inc....
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.